AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

Pharmaceutical stocks often outperform during market downturns because they pay dividends and their products are mostly ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues to start 2025.

AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future expansions expected. Click to read my ABBV update.

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

AbbVie's first-quarter results improved with ... The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 71% to $3.43 billion, and Rinvoq, which logged a 57% gain ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns.

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...